MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 529815 | Name: KR-30450

Description:

WARNING: This product is for research use only, not for human or veterinary use.

KR-30450 is potassium channel agonist potentially for the treatment of hypertension.

Chemical Structure

KR-30450
KR-30450
CAS#172489-10-0

Theoretical Analysis

MedKoo Cat#: 529815

Name: KR-30450

CAS#: 172489-10-0

Chemical Formula: C17H18N2O6

Exact Mass: 346.1165

Molecular Weight: 346.34

Elemental Analysis: C, 58.96; H, 5.24; N, 8.09; O, 27.72

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
KR-30450; SKP-450; KR30450; SKP450; KR 30450; SKP 450
IUPAC/Chemical Name
(R)-1-(2-(1,3-dioxolan-2-yl)-2-methyl-6-nitro-2H-chromen-4-yl)pyrrolidin-2-one
InChi Key
NJJPKIPOZSWUHV-QGZVFWFLSA-N
InChi Code
InChI=1S/C17H18N2O6/c1-17(16-23-7-8-24-16)10-13(18-6-2-3-15(18)20)12-9-11(19(21)22)4-5-14(12)25-17/h4-5,9-10,16H,2-3,6-8H2,1H3/t17-/m1/s1
SMILES Code
O=C1N(C2=C[C@](C)(C3OCCO3)OC4=C2C=C([N+]([O-])=O)C=C4)CCC1
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 346.34 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Jung YS, Moon CH, Cho TS, Yoo SE, Shin HS. Cardioprotective effects of KR-30450, a novel K+(ATP) opener, and its major metabolite KR-30818 on isolated rat hearts. Jpn J Pharmacol. 1998 Jan;76(1):65-73. PubMed PMID: 9517406. 2: Kwak YG, Park SK, Kang HS, Kim JS, Chae SW, Cho KP, Yoo SE, Kim D. KR-30450, a newly synthesized benzopyran derivative, activates the cardiac ATP-sensitive K+ channel. J Pharmacol Exp Ther. 1995 Nov;275(2):807-12. PubMed PMID: 7473170. 3: Kwan YW, To KW, Lau WM, Tsang SH. Comparison of the vascular relaxant effects of ATP-dependent K+ channel openers on aorta and pulmonary artery isolated from spontaneously hypertensive and Wistar-Kyoto rats. Eur J Pharmacol. 1999 Jan 22;365(2-3):241-51. PubMed PMID: 9988108. 4: Shin HS, Seo HW, Oh JH, Lee BH. Antihypertensive effects of the novel potassium channel activator SKP-450 and its major metabolites in rats. Arzneimittelforschung. 1998 Oct;48(10):969-78. PubMed PMID: 9825113. 5: Jang IJ, Yu KS, Shon JH, Bae KS, Cho JY, Yi SY, Shin SG, Ryu KH, Cho YB, Kim DK, Yoo SE. Pharmacokinetic/pharmacodynamic evaluation of a novel potassium channel opener, SKP-450, in healthy volunteers. J Clin Pharmacol. 2000 Jul;40(7):752-61. PubMed PMID: 10883417. 6: Kim HH, Yoo SE, Lee WS, Rhim BY, Hong KW. SKP-450 inhibits migration and DNA synthesis stimulated by oxidized low density lipoprotein in smooth muscle cells. Eur J Pharmacol. 1999 Nov 3;383(3):373-9. PubMed PMID: 10594331. 7: Hong KW, Shin HS, Kim CD, Shin YW, Yoo Se. Pharmacological profiles of SKP-450 and its family, a K+ channel opener, in comparison with levcromakalim. Pharmacol Res. 1998 Sep;38(3):191-7. PubMed PMID: 9782069. 8: Cheon HG, Kim HJ, Mo HK, Yoo SE, Lee BH. Anti-ulcer activity of SKP-450, a novel potassium channel activator, in rats. Pharmacol Res. 1999 Sep;40(3):243-8. PubMed PMID: 10479468. 9: Baek M, Chung HS, Kim Y, Kim DH. Disposition and metabolism of 2-(2''(1'',3''-dioxolan-2-yl)-2- methyl-4-(2'-oxopyrrolidin-1-Yl)-6-nitro-2h-1-benzopyran (SKP-450) in rats. Drug Metab Dispos. 1999 Apr;27(4):510-6. PubMed PMID: 10101146. 10: Lee EY, Lim DM, Yoo SE, Kim DK, Paik YK. Biochemical basis for a cholesterol-lowering activity of 2-[2"-(1",3"-dioxolane)]-2-methyl-4-(2'-oxo-1'-pyrrolidinyl)-6- nitro-2H-1-benzopyran (SKP-450), a novel antihypertensive agent. Biochem Pharmacol. 1999 Mar 1;57(5):579-82. PubMed PMID: 9952322. 11: Shin HS, Seo HW, Yoo SE, Lee BH. Cardiovascular pharmacology of SKP-450, a new potassium channel activator, and its major metabolites SKP-818 and SKP-310. Pharmacology. 1998 Mar;56(3):111-24. PubMed PMID: 9532610. 12: Lee BH, Yoo SE, Shin HS. Hemodynamic profile of SKP-450, a new potassium-channel activator. J Cardiovasc Pharmacol. 1998 Jan;31(1):85-94. PubMed PMID: 9456282.

View History

KRH-3955 tartrate

KRH-3955 tartrate